CX-4945, a selective inhibitor of casein kinase 2, synergizes with B cell receptor signaling inhibitors in inducing diffuse large B cell lymphoma cell death.

CONCLUSION: These findings suggest a role for CK2 downstream of the BCR in controlling survival pathways crucial for cell growth of different DLBCL subtypes. Also, the use of CX-4945 in combination with BCR signaling blockers could represent a novel rational therapeutic approach in DLBCL.
PMID: 28460620 [PubMed - as supplied by publisher]

Source: Current Cancer Drug Targets - April 26, 2017 Category: Cancer & Oncology Authors: Mandato E, Nunes SC, Zaffino F, Casellato A, Macaccaro P, Tubi LQ, Visentin A, Trentin L, Semenzato G, Piazza F Tags: Curr Cancer Drug Targets Source Type: research